Search research articles
Contact Us
Filters
Showing results (71-80 of 101) with videos related to
Page
of 11
Sort By:
Urologic Oncology
|
December 14, 2011
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial
Donna L Berry, Barbara Halpenny, Fangxin Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)
Lynne I Wagner, Fengmin Zhao, Fangxin Hong, et al.
Cell
|
April 9, 2008
Rapid synthesis of auxin via a new tryptophan-dependent pathway is required for shade avoidance in plants
Yi Tao, Jean-Luc Ferrer, Karin Ljung, et al.
JTO Clinical and Research Reports
|
September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402
Brad S Kahl, Fangxin Hong, Michael E Williams, et al.
Blood Cancer Journal
|
April 2, 2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients
Samilia Obeng-Gyasi, Noah Graham, Shaji Kumar, et al.
Blood
|
February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
Yu-Tzu Tai, Ender Soydan, Weihua Song, et al.
British Journal of Haematology
|
March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2010
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia
Irene M Ghobrial, Aldo Roccaro, Fangxin Hong, et al.
The Journal of Urology
|
July 30, 2017
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial
Donna L Berry, Fangxin Hong, Traci M Blonquist, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 101) with videos related to
Sort By:
Page
of 11
Urologic Oncology
|
December 14, 2011
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial
Donna L Berry, Barbara Halpenny, Fangxin Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 22, 2015
Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT)
Lynne I Wagner, Fengmin Zhao, Fangxin Hong, et al.
Cell
|
April 9, 2008
Rapid synthesis of auxin via a new tryptophan-dependent pathway is required for shade avoidance in plants
Yi Tao, Jean-Luc Ferrer, Karin Ljung, et al.
JTO Clinical and Research Reports
|
September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Marissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 27, 2014
Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402
Brad S Kahl, Fangxin Hong, Michael E Williams, et al.
Blood Cancer Journal
|
April 2, 2022
Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients
Samilia Obeng-Gyasi, Noah Graham, Shaji Kumar, et al.
Blood
|
February 7, 2009
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
Yu-Tzu Tai, Ender Soydan, Weihua Song, et al.
British Journal of Haematology
|
March 13, 2016
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
Michael E Williams, Fangxin Hong, Randy D Gascoyne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 28, 2010
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia
Irene M Ghobrial, Aldo Roccaro, Fangxin Hong, et al.
The Journal of Urology
|
July 30, 2017
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial
Donna L Berry, Fangxin Hong, Traci M Blonquist, et al.
Page
of 11